Goldman Sachs Maintains Neutral on Ambrx Biopharma, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Corinne Jenkins has maintained a Neutral rating on Ambrx Biopharma (NASDAQ:AMAM) and reduced the price target from $10 to $9.
November 15, 2023 | 3:24 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Goldman Sachs analyst Corinne Jenkins has maintained a Neutral rating on Ambrx Biopharma but lowered the price target from $10 to $9.
The reduction in price target by a major analyst like Goldman Sachs suggests a less optimistic outlook on the stock's value, which could lead to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100